Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQZC0U)

Drug Name

MCL-129 Drug Info

Synonyms

MCL-129; CHEMBL362985; SCHEMBL5318500; SLGLZEJKMBCODK-UHFFFAOYSA-N; BDBM50166529; PDSP2_001273; PDSP1_001289; 1-(2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl)-4-(4-(2-methoxynaphthalen-1-yl)butyl)piperazine; 1-[2-(4-fluorophenyl)-2-(4-isopropylhexahydro-1-pyrazinyl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]hexahydropyrazine; (+/-)-1-[2-(4-fluorophenyl)-2-(4-isopropylpiperazin-1-yl)ethyl]-4-[4-(2-methoxy-1-naphthyl)butyl]piperazine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10098971
TTD Drug ID: DMQZC0U

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Melanocortin receptor 4 (MC4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylnaltrexone bromide	DMZTGN2	Opioid-induced constipation	DB32.1	Approved	[2]
Bremelanotide	DM20LIM	Hypoactive sexual desire dysfunction	HA00	Approved	[3]
Setmelanotide	DMPVRN9	Obesity	5B81	Approved	[4]
Amylin	DMWDEN0	N. A.	N. A.	Phase 4	[5]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[2]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[6]
PF-446687	DML38VU	Female sexual arousal dysfunction	HA01.1	Phase 2	[7]
AP-1030	DMBGA35	Metabolic disorder	5C50-5D2Z	Phase 1/2	[8]
PF-07258669	DM3CJ5N	Malnutrition	5B50-5B71	Phase 1	[9]
PT-14	DMYM9JL	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanocortin receptor 4 (MC4R)	TTD0CIQ	MC4R_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem. 2007 Mar 1;15(5):1989-2005.
2	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
6	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
7	Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
8	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9	Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
10	The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.